The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Favorable tolerability and early outcomes with full dose lenalidomide in older adults with NDMM
Othman Akhtar, MD, Medical College of Wisconsin, Milwaukee, WI, discusses an investigation into the optimal lenalidomide dosing strategy for older adults with newly diagnosed multiple myeloma (NDMM). This analysis showed that the majority of patients over 70 years old receiving lenalidomide-containing triplet or quadruplet induction regimens tolerated the recommended starting dose of 25 milligrams (mg) well, with low treatment-related discontinuations and dose modifications. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
